Implications of Genetic, Biological and Clinical Parameters in Patients With Richter Syndrome: A Monocentric Experience

Hematol Oncol. 2025 Jan;43(1):e70028. doi: 10.1002/hon.70028.

¹ Dipartimento di scienze di laboratorio ed ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOSD Leucemia Linfatica Cronica, Roma, Italy.
² Istituto di Ematologia, Università Cattolica del Sacro Cuore, Roma, Italy.
³ Department of Medicine 5, Haematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Universitätsklinikum, Erlangen, Germany.
⁴ UniCamillus, Institute of Pathology, Roma, Italy.
⁵ Istituto di Patologia, Fondazione Policlinico Gemelli Roma, Università Cattolica del Sacro Cuore, Roma, Italy.
⁶ Molecular Hematology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.
⁷ Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
⁸ Facility of Epidemiology and Biostatistics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

No abstract available

Keywords: CLL; Richter syndrome; chemo‐immunotherapy; targeted therapy.

Publication types